in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J Cannabis Ther
3:121– 152
Hanus LO, Tchilibon S, Ponde DE, Breuer A, Fride E, Mechoulam R (2005) Enantiomeric
cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org Biomol Chem
3:1116– 1123
Harvey DJ, Mechoulam R (1990) Metabolites of cannabidiol identified in human urine.
Xenobiotica (the fate of foreign compounds in biological systems) 20:303– 320
Hawksworth GM, McArdle K (2004) Metabolism and pharmacokinetics of cannabinoids. In:
Guy G, Whittle B, Robson P (eds)The Medicinal Uses of Cannabis and Cannabinoids.
Pharmaceutical Press, London, pp 205– 228
Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, Paolini JL, Thiele EA
(2016) Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis
complex. Epilepsia 57:1617– 1624
Hill AJ, Jones NA, Smith I, Hill CL, Williams CM, Stephens GJ, Whalley BJ (2014)
Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer
anticonvulsant effects per se. Neurosci Lett 566:269– 274
Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, Russo E, Whalley BJ, Di
Marzo V, Stephens GJ (2014) Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV)
and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1
(TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS
Chem Neurosci 5:1131– 1141
Izquierdo I, Orsingher OA, Berardi AC (1973) Effect of cannabidiol and of otherCannabis sativa
compounds on hippocampal seizure discharges. Psychopharmacologia 28:95– 102
Jones PG, Falvello L, Kennard O, Sheldrick GM, Mechoulam R (1977) Cannabidiol. Acta
Crystallogr Sect B 33:3211– 3214
Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, Stephens GJ (2010)
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.
J Pharmacol Exp Ther 332:569– 577
Jones NA, Glyn SE, Akiyama S, Hill TDM, Hill AJ, Weston SE, Burnett MDA, Yamasaki Y,
Stephens GJ, Whalley BJ, Williams CM (2012) Cannabidiol exerts anti-convulsant effects in
animal models of temporal lobe and partial seizures. Seizure 21:344– 352
Laprairie RB, Bagher AM, Kelly ME, Dupre DJ, Denovan-Wright EM (2014) Type 1 cannabinoid
receptor ligands display functional selectivity in a cell culture model of striatal medium spiny
projection neurons. J Biol Chem 289:24845– 24862
Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015) Cannabidiol is a negative
allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790– 4805
Ledgerwood CJ, Greenwood SM, Brett RR, Pratt JA, Bushell TJ (2011) Cannabidiol inhibits
synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways.
Br J Pharmacol 162:286– 294
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M,
Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic
symptoms of schizophrenia. Transl Psychiatry 2:e94
Martin-Moreno AM, Reigada D, Ramirez BG, Mechoulam R, Innamorato N, Cuadrado A, de
Ceballos ML (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro
and in vivo: relevance to Alzheimer’s disease. Mol Pharmacol 79:964– 973
McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol and Delta(9) -
tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic
review. Br J Pharmacol 172:737– 753
Mechoulam R, Carlini EA (1978) Toward drugs derived from cannabis. Die Naturwissenschaften
65:174– 179
Mechoulam R, Hanus L (2002) Cannabidiol: an overview of some chemical and pharmacological
aspects. Part I: chemical aspects. Chem Phys Lipids 121:35– 43
Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE (1984) Single dose
kinetics of cannabidiol in man. In: Agurell S, Dewey WL and Willette RE (eds) The
11 Cannabidiol as a Treatment for Seizures, Convulsions and Epilepsy 259